Home » Topics » Ear, nose and throat, BioWorld Science

Ear, nose and throat, BioWorld Science
RSS

Interim analysis completed for phase III trial of AM-101 in post-acute tinnitus

March 11, 2015

Otonomy submits NDA to the FDA for AuriPro

March 2, 2015

Next Science wound gel inhibits biofilm development in ear infection models

Feb. 4, 2015

Auris Medical updates on phase III trial of AM-101 in tinnitus

Jan. 16, 2015

FDA approves ear drop formulation of finafloxacin for acute otitis externa

Dec. 18, 2014

Salvat reports topline phase III results for combination otic solution in AOMT

Oct. 3, 2014

Phase Ib data of synthetic cis-retinoid therapy for patients with genetic retinal defects

Sep. 19, 2014

NicOx obtains antiviral eye drop program from Marinomed

Sep. 17, 2014

Otonomy releases phase III data for AuriPro in middle ear effusion

July 10, 2014

Autifony Therapeutics awarded grant to support phase IIa study of AUT-00063 for tinnitus

June 10, 2014

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026